Unit
Brustzentrum St.Gallen
BZ · Dept. IV
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
Fontanella C, Schneeweiss A, Paepke S, Jackisch C, Mehta K, Nekljudova V, Untch M, Neven P, von Minckwitz G, Huober J, Hilfrich J, Hanusch C, Lederer B, Gade S, Vanoppen M, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Loibl S. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 2015; 150:127-39.
Feb 13, 2015Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
Feb 13, 2015Breast Cancer Res Treat 2015; 150:127-39
Fontanella Caterina, Schneeweiss Andreas, Paepke Stefan, Jackisch Christian, Mehta Keyur, Nekljudova Valentina, Untch Michael, Neven Patrick, von Minckwitz Gunter, Huober Jens, Hilfrich Jörn, Hanusch Claus, Lederer Bianca, Gade Stephan, Vanoppen Mieke, Blohmer Jens Uwe, Costa Serban Dan, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Loibl Sibylle
Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study
Klauschen F, Denkert C, Dietel M, Lederer B, Mehta K, Erbstößer E, Rüdiger T, Huober J, Blohmer J, Gerber B, Loibl S, Schmitt W, Wienert S, von Minckwitz G. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. Clin Cancer Res 2014; 21:3651-7.
Dec 11, 2014Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study
Dec 11, 2014Clin Cancer Res 2014; 21:3651-7
Klauschen Frederick, Denkert Carsten, Dietel Manfred, Lederer Bianca, Mehta Keyur, Erbstößer Erhard, Rüdiger Thomas, Huober Jens, Blohmer Jens-Uwe, Gerber Bernd, Loibl Sibylle, Schmitt Wolfgang D, Wienert Stephan, von Minckwitz Gunter
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
Gnant M, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R, Steger G, Eiermann W, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2014; 26:313-20.
Nov 17, 2014Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
Nov 17, 2014Ann Oncol 2014; 26:313-20
Gnant M, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R, Steger G, Eiermann W, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer Michael, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
Krop I, Welslau M, Samant M, Miles D, Lu M, Huober J, Guardino E, Blackwell K, Lin N, Diéras V. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 2014; 26:113-119.
Oct 29, 2014Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
Oct 29, 2014Ann Oncol 2014; 26:113-119
Krop I E, Welslau M, Samant M, Miles D, Lu M, Huober Jens, Guardino E, Blackwell K, Lin N U, Diéras V
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
Lindner J, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, Engels K, Huober J, Sinn B, Loibl S, Denkert C, Ataseven B, Fasching P, Pfitzner B, Gerber B, Gade S, Darb-Esfahani S, von Minckwitz G. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol 2014; 26:95-100.
Oct 29, 2014Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
Oct 29, 2014Ann Oncol 2014; 26:95-100
Lindner J L, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, Engels K, Huober Jens, Sinn B V, Loibl S, Denkert C, Ataseven B, Fasching P A, Pfitzner B M, Gerber B, Gade S, Darb-Esfahani S, von Minckwitz G
The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies
Ruan X, Seeger H, Wallwiener D, Huober J, Mueck A. The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies. Arch Gynecol Obstet 2014; 291:1141-6.
Oct 16, 2014The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies
Oct 16, 2014Arch Gynecol Obstet 2014; 291:1141-6
Ruan Xiangyan, Seeger Harald, Wallwiener Diethelm, Huober Jens, Mueck Alfred O
Regulation of endothelial permeability in the primate corpora lutea: implications for ovarian hyperstimulation syndrome
Herr D, Bekes I, Wulff C. Regulation of endothelial permeability in the primate corpora lutea: implications for ovarian hyperstimulation syndrome. Reproduction 2014; 149:R71-9.
Oct 9, 2014Regulation of endothelial permeability in the primate corpora lutea: implications for ovarian hyperstimulation syndrome
Oct 9, 2014Reproduction 2014; 149:R71-9
Herr Daniel, Bekes Inga, Wulff Christine
Adjuvant bisphosphonates in breast cancer treatment
Knauer M, Thürlimann B. Adjuvant bisphosphonates in breast cancer treatment. Breast Care (Basel) 2014; 9:319-22.
Oct 1, 2014Adjuvant bisphosphonates in breast cancer treatment
Oct 1, 2014Breast Care (Basel) 2014; 9:319-22
Knauer Michael, Thürlimann Beat
Bone targeted therapy in breast cancer - an old concept but still much to do
Huober J, Thürlimann B. Bone targeted therapy in breast cancer - an old concept but still much to do. Breast Care (Basel) 2014; 9:310.
Oct 1, 2014Bone targeted therapy in breast cancer - an old concept but still much to do
Oct 1, 2014Breast Care (Basel) 2014; 9:310
Huober Jens, Thürlimann Beat
Uncommon case of brain metastasis in a patient with a history of heavy smoking.
Scharl M, Bode B, Rushing E, Knuth A, Rordorf T. Uncommon case of brain metastasis in a patient with a history of heavy smoking. Curr Oncol 2014; 21:e728-31.
Oct 1, 2014Uncommon case of brain metastasis in a patient with a history of heavy smoking.
Oct 1, 2014Curr Oncol 2014; 21:e728-31
Scharl Michael, Bode B, Rushing Elisabeth Jane, Knuth A, Rordorf Tamara
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
Salmen J, Sohn C, Fehm T, Mohrmann S, Loehberg C, Hein A, Schulz-Wendtland R, Hartkopf A, Brucker S, Wallwiener D, Friese K, Hartmann A, Beckmann M, Janni W, Rom J, Heil J, Neugebauer J, Fasching P, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Rack B. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Res Treat 2014; 148:143-51.
Sep 25, 2014Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
Sep 25, 2014Breast Cancer Res Treat 2014; 148:143-51
Salmen Jessica, Sohn Christof, Fehm Tanja, Mohrmann Svjetlana, Loehberg Christian R, Hein Alexander, Schulz-Wendtland Ruediger, Hartkopf Andreas D, Brucker Sara Y, Wallwiener Diethelm, Friese Klaus, Hartmann Arndt, Beckmann Matthias W, Janni Wolfgang, Rom Joachim, Heil Joerg, Neugebauer Julia, Fasching Peter A, Haeberle Lothar, Huober Jens, Wöckel Achim, Rauh Claudia, Schuetz Florian, Weissenbacher Tobias, Kost Bernd, Stickeler Elmar, Klar Maximilian, Orlowska-Volk Marzenna, Windfuhr-Blum Marisa, Rack Brigitte
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer
Loibl S, Fasching P, Andre F, Lindner J, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Pfitzner B, Huober J, Heinrichs C, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm D, Sinn P, Khandan F, Eidtmann H, Dohnal K, Denkert C. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014; 32:3212-20.
Sep 8, 2014PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer
Sep 8, 2014J Clin Oncol 2014; 32:3212-20
Loibl Sibylle, Fasching Peter A, Andre Fabrice, Lindner Judith L, Sotiriou Christos, Dykgers August, Guo Sanxing, Gade Stephan, Nekljudova Valentina, Loi Sherene, Untch Michael, Pfitzner Berit, Huober Jens, Heinrichs Clemens, von Minckwitz Gunter, Schneeweiss Andreas, Paepke Stefan, Lehmann Annika, Rezai Mahdi, Zahm Dirk M, Sinn Peter, Khandan Fariba, Eidtmann Holger, Dohnal Karel, Denkert Carsten
Trends in survival from oesophageal cancer in Switzerland
Ruhstaller T, Voker A, Lorez M. Trends in survival from oesophageal cancer in Switzerland. Schweizer Krebsbulletin 2014; 3:227-231.
Sep 1, 2014Trends in survival from oesophageal cancer in Switzerland
Sep 1, 2014Schweizer Krebsbulletin 2014; 3:227-231
Ruhstaller Thomas, Voker Arndt, Lorez Mathias
Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients
Bock C, Rack B, Huober J, Andergassen U, Jeschke U, Doisneau-Sixou S. Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients. Future Oncol 2014; 10:1751-65.
Aug 1, 2014Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients
Aug 1, 2014Future Oncol 2014; 10:1751-65
Bock Carolin, Rack Brigitte, Huober Jens, Andergassen Ulrich, Jeschke Udo, Doisneau-Sixou Sophie
Sentinel Node Biopsy nach adjuvanter Chemotherapie bei N1–ycN0
Knauer M. Sentinel Node Biopsy nach adjuvanter Chemotherapie bei N1–ycN0 - Können wir auf die Axilladissektion nach einem Downstaging der Lymphknoten verzichten?. Leading Opinions Hämatologie / Onkologie 2014:42-44.
Jul 1, 2014Sentinel Node Biopsy nach adjuvanter Chemotherapie bei N1–ycN0
Jul 1, 2014Leading Opinions Hämatologie / Onkologie 2014:42-44
Knauer Michael
Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Rordorf T, Hassan A, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbanec D, Yildiz R, Yücel S, Zekri J, Oyan B, ĀăąĆĉČĎ Ā, Swiss Group for Clinical Cancer Research (SAKK). Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup. Breast 2014; 23:511-25.
Jun 27, 2014Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Jun 27, 2014Breast 2014; 23:511-25
Rordorf Tamara, Hassan Azza Adel, Azim Hamdy, Alexandru Eniu, Er Ozlem, Gokmen Erhan, Güral Zeynep, Mardiak Jozef, Minchev Velko, Peintinger Florentia, Szendroi Miklos, Takac Itzok, Tesarova Petra, Vorobiof Daniel, Vrbanec Damir, Yildiz Ramazan, Yücel Serap, Zekri Jamal, Oyan Basak, ĀăąĆĉČĎ Ā ā Ă ă Ą ą Ć ć Ĉ ĉ Ċ ċ Č č Ď ď Đ đ Ē ē Ĕ ĕ Ė ė Ę ę Ě ě Ĝ ĝ Ğ ğ Ġ ġ Ģ ģ Ĥ ĥ Ħ ħ Ĩ ĩ Ī ī Ĭ ĭ Į į İ ı IJ ij Ĵ ĵ Ķ ķ ĸ Ĺ ĺ Ļ ļ Ľ ľ Ŀ ŀ Ł ł Ń ń Ņ ņ Ň ň ʼn Ŋ ŋ Ō ō Ŏ ŏ Ő ő Œ œ Ŕ ŕ Ŗ ŗ Ř ř Ś ś Ŝ ŝ Ş ş Š š Ţ ţ Ť ť Ŧ ŧ Ũ ũ Ū ū Ŭ ŭ Ů ů Ű ű Ų ų Ŵ ŵ Ŷ ŷ Ÿ Ź ź Ż ż Ž ž ſ, Swiss Group for Clinical Cancer Research (SAKK)
Comparison of a standard CO2 pressure pneumoperitoneum insufflator versus AirSealTM: study protocol of a randomized controlled trial
Luketina R, Knauer M, Köhler G, Koch O, Strasser K, Egger M, Emmanuel K. Comparison of a standard CO2 pressure pneumoperitoneum insufflator versus AirSealTM: study protocol of a randomized controlled trial. Trials 2014; 15:239.
Jun 20, 2014Comparison of a standard CO2 pressure pneumoperitoneum insufflator versus AirSealTM: study protocol of a randomized controlled trial
Jun 20, 2014Trials 2014; 15:239
Luketina Ruzica Rosalia, Knauer Michael, Köhler Gernot, Koch Oliver Owen, Strasser Klaus, Egger Margot, Emmanuel Klaus
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371:107-18.
Jun 1, 2014Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Jun 1, 2014N Engl J Med 2014; 371:107-18
Pagani Olivia, Winer Eric P, Rabaglio-Poretti Manuela, Maibach Rudolf, Ruepp Barbara, Giobbie-Hurder Anita, Price Karen N, Bernhard Jürg, Luo Weixiu, Ribi Karin, Viale Giuseppe, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Francis Prudence A, TEXT and SOFT Investigators, Ruhstaller Thomas, Crivellari Diana, Puglisi Fabio, Regan Meredith M, Walley Barbara A, Fleming Gini F, Colleoni Marco, Láng István, Gomez Henry L, Tondini Carlo, Burstein Harold J, Perez Edith A, Ciruelos Eva, Stearns Vered, Bonnefoi Hervé R, Martino Silvana, Geyer Charles E, Pinotti Graziella, International Breast Cancer Study Group
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2014; 25:1551-7.
May 14, 2014Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
May 14, 2014Ann Oncol 2014; 25:1551-7
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober Jens, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W
Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?
Knauer M, Filipits M, Dubsky P. Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?. Breast Care (Basel) 2014; 9:97-100.
May 1, 2014Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?
May 1, 2014Breast Care (Basel) 2014; 9:97-100
Knauer Michael, Filipits Martin, Dubsky Peter